Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | May 25, 2023 | May 30, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date May 25, 2023 · Filed May 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,508 |
Reported balance
After 2023-05-25 transaction · row 1
1 source rowRow 1 · 2023-05-25 · Grant · Acquired 33,847 · Balance 57,508 F1: Consists of restricted stock units granted under the company's Stock Incentive Plan, as amended and restated. These restricted stock units vest in one installment beginning on the day prior to the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted under the company's Stock Incentive Plan, as amended and restated. These restricted stock units vest in one installment beginning on the day prior to the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2023 Filed May 30, 2023 19:08 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 33,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000108 · wk-form4_1685488079.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,508 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan, as amended and restated. These restricted stock units vest in one installment beginning on the day prior to the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| May 26, 2022 Filed May 31, 2022 16:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000093 · wf-form4_165402855664092.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,661 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 20, 2021 Filed May 24, 2021 16:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000085 · wf-form4_162188987773805.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,215 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 26, 2020 Filed May 27, 2020 17:10 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 4,385 | $85.15 | $373,373.10 |
DisclosureSEC source: 0001367644-20-000086 · wf-form4_159061381707489.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,188 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Hauer. F3 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.14 to $86.23. Read SEC document |
| May 21, 2020 Filed May 26, 2020 08:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 2,821 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000074 · wf-form4_159049687772300.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,573 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 16:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 6,572 | $70.00 | $460,040.00 |
DisclosureSEC source: 0001367644-20-000012 · wf-form4_158266609423712.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,752 F1 · security: Consists of restricted stock units granted under the Company's stock incentive plan, as amended and restated. F2 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Hauer. Read SEC document |
| May 23, 2019 Filed May 28, 2019 20:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012277 · doc1.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,324 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 16:27 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 8,375 | $52.16 | $436,876.01 |
DisclosureSEC source: 0001140361-18-027687 · doc1.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,588 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.63, inclusive. Read SEC document |
| May 24, 2018 Filed May 24, 2018 18:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025551 · doc1.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,963 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the day prior to the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| January 23, 2018 Filed Jan 24, 2018 20:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 2,577 | $50.25 | $129,494.25 |
DisclosureSEC source: 0001140361-18-003133 · doc1.xml · nonDerivative · entry 3 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,068 F1 · price: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Hauer. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 20:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,152 | $0.00 Strike: $25.47 | $0.00 |
DisclosureSEC source: 0001140361-18-003133 · doc1.xml · derivative · entry 4 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,152 shares Expires 2022-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted on January 22, 2015 under the company's stock incentive plan as amended and restated. F4 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 20:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 5,152 | $50.91 | $262,292.44 |
DisclosureSEC source: 0001140361-18-003133 · doc1.xml · nonDerivative · entry 2 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,645 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.25 to $51.25, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F1 · price: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Hauer. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 20:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 5,152 | $25.47 | $131,221.44 |
DisclosureSEC source: 0001140361-18-003133 · doc1.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Hauer. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 16:32 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,153 | $0.00 Strike: $25.47 | $0.00 |
DisclosureSEC source: 0001140361-17-032607 · doc1.xml · derivative · entry 3 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,152 Underlying: Common Stock · 5,153 shares Expires 2022-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Consists of an option granted on January 22, 2015 under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 16:32 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 10,776 | $35.83 | $386,149.34 |
DisclosureSEC source: 0001140361-17-032607 · doc1.xml · nonDerivative · entry 2 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,645 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.70 to $36.05, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 16:32 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,153 | $25.47 | $131,246.91 |
DisclosureSEC source: 0001140361-17-032607 · doc1.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,421 F1 · security: Consists of an option granted on January 22, 2015 under the company's stock incentive plan as amended and restated. Read SEC document |
| May 25, 2017 Filed May 26, 2017 14:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022488 · doc1.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,268 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 2,576 | $31.27 | $80,558.48 |
DisclosureSEC source: 0001140361-17-011623 · doc1.xml · nonDerivative · entry 4 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,009 F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.25 to $31.32, inclusive. Read SEC document |
| August 01, 2016 Filed Mar 10, 2017 16:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) · Derivative | 905 | $0.00 Strike: $25.47 | $0.00 |
DisclosureSEC source: 0001140361-17-011623 · doc1.xml · derivative · entry 5 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,305 Underlying: Common Stock · 10,305 shares Expires 2022-01-21 F5 · security: Consists of an option granted on January 22, 2015 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F6 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 01, 2016 Filed Mar 10, 2017 16:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 577 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-011623 · doc1.xml · nonDerivative · entry 3 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,585 F3 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019. Read SEC document |
| August 01, 2016 Filed Mar 10, 2017 16:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 604 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-011623 · doc1.xml · nonDerivative · entry 2 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,008 F2 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018. Read SEC document |
| August 01, 2016 Filed Mar 10, 2017 16:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 453 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-011623 · doc1.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,404 F1 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in January 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.